15th June 2007
Clinical Trials & Research
Current Clinical Trials:
NSABP B38
A phase III, Adjuvant trial comparing Three Chemotherapy Regimens in Women
with node-positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide
(TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel
(DD AC 
P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC
PG) Status: Ongoing but closed to recruitment
NSABP C-08/ICORG 05-02
A phase III clinical trial comparing infusional (5-FU,Leucovorin, and Oxaliplatin
(Mfolfox6) q2weeks with Bevacizumab to the same regimen without Bevacizumab
for the treatment of patients with resected stages II and stages III carcinoma
of the colon.
Status: Ongoing but closed to recruitment
FACE
A randomized, multicentre Phase IIIb, open label study of letrozole vs.
anastrozole in the adjuvant treatment of post menopausal women with hormone
receptor and node positive breast cancer
Status: Open & recruiting
AZURE
Does adjuvant zoledronic acid reduce recurrence in patients with high
risk localised breast cancer?
Status: Ongoing but closed to recruitment
PAD
A Phase II study assess the Safety, Efficacy and Tolerability of Combination
Therapy with Velcade™ (Bortezomib), Doxorubicin and Dexamethasone
(PAD) as therapy for patients with relapsed or refractory Multiple Myeloma.
Status: Open & recruiting
EGF30008:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study
Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone
Receptor-Positive Advanced or Metastatic Breast Cancer.
Status: Closed
EGF100151:
A Phase II/III, Randomized, Open-Label, Two-arm, Multicenter Study Comparing
GW572016 and Capecitabine (Xeloda®) versus Capecitabine in Women with
Refractory Advanced or Metastatic Breast Cancer
Status: Closed
IBIS II
DCIS Study: International Breast cancer Intervention Study
(IBIS) of tamoxifen vs. anastrozole in postmenopausal women with Ductal
Carcinoma In-Situ (DCIS)
Prevention Study: International Breast cancer Intervention
Study (IBIS) of anastrozole vs placebo in postmenopausal women at increased
risk of breast cancer.
Bone Sub study: International Breast cancer Intervention
Study (IBIS) of anastrozole vs placebo in postmenopausal women at increased
risk of breast cancer.
Status: Open & recruiting
R-CHOP 14 V 21:
A phase III multicentre randomised clinical trial comparing rituximab with
CHOP given every 14 days and rituximab with CHOP given every 21 days for
the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s
lymphoma.
Status: Pending
CORAL study:
A randomized study of ICE plus rituximab (R-ICE) versus DHAP plus rituximab
(R-DHAP) in previously treated patients with CD 20 positive diffuse large
b-cell lymphoma, eligible for transplantation followed by randomized maintenance
treatment with rituximab
Status: Pending
Watch and Wait Trial:
An intergroup randomised trial of rituximab versus a watch and wait strategy
in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma
(Grades 1, 2 and 3a).
Status: Pending
COIN
A three-arm randomised controlled trial comparing either continuous chemotherapy
plus cetuximab or INtermittent chemotherapy with standard continuous palliative
combination chemotherapy with oxaliplatin and a fluoropyrimidine in first
line treatment of metastatic colorectal cancer.
Status: Open & recruiting
Useful Links
- ICORG (Irish Clinical Oncologists Research Group)
- UL (School of Nursing)
- UCD (School of Nursing)
- Stokes Research Institute / UL
Disclaimer | Privacy Statement
Mid-Western Cancer Centre, Mid-Western
Regional Hospital, Dooradoyle, Limerick.
Tel: +353 (061) 482900 08.30 am to 17.30, Mon-Fri
|
